Broken String Biosciences is a genomics company with the goal of developing safer cell and gene therapies by assessing the stability of the genome. The Company is building a technology platform pipeline that will drive the development of cell and gene therapies that are safer by design. Its core technology, INDUCE-seq™, is a Next Generation Sequencing (NGS)-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and to evaluate the associated genetic risks.

https://www.brokenstringbio.com

• Founded by Felix Dobbs, PhD, Prof. Simon Reed, Patrick van Eijk, PhD & Simon Kerr in 2020
• Initial Investment in September 2021